Company: Pfizer Inc.
Ticker: PFE
Form: 10-K
Filed: 2026-02-26
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Pfizer Inc.'s operating cash flow in fiscal year 2025?
Question Type: value_lookup

Concept: NetCashProvidedByUsedInOperatingActivities
Answer (Numeric): 11704.0
Answer (Display): $11,704 million
Unit: USD millions

Evidence:
[{"chunk_id": "214", "equivalent_chunk_ids": ["214"], "section": "Consolidated Statements of Cash Flows", "supports": ["main"], "text": "Pfizer Inc. and Subsidiary Companies\nYear Ended December 31,\n(MILLIONS)\nOperating Activities\nNet income before allocation to noncontrolling interests\n7,812\n8,062\n2,158\nDiscontinued operations—net of tax\nNet income from continuing operations before allocation to noncontrolling interests\n7,787\n8,051\n2,172\nAdjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:\nDepreciation and amortization\n6,592\n7,013\n6,290\nAsset write-offs and impairments\n5,270\n4,242\n3,408\nDeferred taxes\n2,133\n2,102\n3,442\nShare-based compensation expense\nBenefit plan contributions in excess of expense/income\nInventory write-offs and related charges associated with COVID-19 products\n(a)\n6,199\nOther adjustments, net\n2,260\n3,492\nOther changes in assets and liabilities, net of acquisitions and divestitures:\nTrade accounts receivable\nInventories\n(a)\n1,169\nOther assets\n1,289\n3,380\nTrade accounts payable\n1,023\nOther liabilities\n(b)\n3,667\n3,115\nOther tax accounts, net\n2,805\n1,345\nNet cash provided by/(used in) operating activities\n11,704\n12,744\n8,700\nInvesting Activities\nPurchases of property, plant and equipment\n2,629\n2,909\n3,907\nPurchases of short-term investments\n14,356\n10,133\n30,974\nProceeds from redemptions/sales of short-term investments\n17,959\n4,128\n39,264\nNet (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less\n2,675\n3,136\n5,174\nPurchases of long-term investments\nProceeds from redemptions/sales of long-term investments\n1,095\n1,570\n1,979\nProceeds from partial sales of investment in Haleon\n(c)\n6,311\n7,040\nAcquisitions of businesses, net of cash acquired\n6,927\n43,430\nOther investing activities, net\nNet cash provided by/(used in) investing activities\n1,351\n2,652\n32,278\nFinancing Activities\nProceeds from short-term borrowings\n8,907\n4,525\nPayments on short-term borrowings\n2,199\n11,226\nNet (payments on)/proceeds from short-term borrowings with original maturities of three months or less\n2,590\n3,161\nProceeds from issuance of long-term debt\n9,678\n30,831\nPayments on long-term debt\n6,757\n2,250\n2,569\nCash dividends paid\n9,771\n9,512\n9,247\nOther financing activities, net\nNet cash provided by/(used in) financing activities\n10,304\n17,140\n26,066\nEffect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents\nNet increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents\n1,810\n2,448\nCash and cash equivalents and restricted cash and cash equivalents, at beginning of period\n1,107\n2,917\nCash and cash equivalents and restricted cash and cash equivalents, at end of period\n1,197\n1,107\n2,917\n- Continued -\nPfizer Inc.\n2025 Form 10-K"}]

Derivation: